PMID- 32838760
OWN - NLM
STAT- MEDLINE
DCOM- 20210414
LR  - 20210414
IS  - 1471-2407 (Electronic)
IS  - 1471-2407 (Linking)
VI  - 20
IP  - 1
DP  - 2020 Aug 24
TI  - OTX1 exerts an oncogenic role and is negatively regulated by miR129-5p in 
      laryngeal squamous cell carcinoma.
PG  - 794
LID - 10.1186/s12885-020-07279-1 [doi]
LID - 794
AB  - BACKGROUND: Orthodenticle homeobox 1 (OTX1) is a transcription factor that plays 
      an important role in various human cancers. However, the function of OTX1 in 
      laryngeal squamous cell carcinoma (LSCC) is largely unknown. We aimed to explore 
      the roles of OTX1 in LSCC and its possible molecular mechanism. METHODS: The 
      expression levels of OTX1 were assessed in LSCC cell lines and tissue samples. We 
      further examined the effect of OTX1 on LSCC progression. The upstream regulator 
      of OTX1 was identified using a computer algorithm and confirmed experimentally. 
      RESULTS: OTX1 was highly expressed in 70.7% (70/99) of LSCC tissue samples. The 
      OTX1 expression in LSCC was significantly correlated with lymph node metastasis. 
      High OTX1 expression in patients with LSCC was correlated with poor prognosis. 
      Knockdown of OTX1 inhibited proliferation, colony formation, migration and 
      invasion in LSCC cells. Knockdown of OTX1 inhibited tumor growth in a xenograft 
      mouse model. Mechanistically, OTX1 might act as a direct target of miR-129-5p. 
      OTX1 enhanced tumorigenicity and tumor growth both in vitro and in vivo. 
      CONCLUSIONS: Our findings support that OTX1 is an oncogene in LSCC tumorigenesis 
      and progression. Furthermore, OTX1 is a direct target of miR-129-5p in LSCC 
      cells. Taken together, OTX1 is a promising diagnostic and therapeutic marker for 
      LSCC.
FAU - Tu, Xiu-Ping
AU  - Tu XP
AD  - Department of Otorhinolaryngology, Guangdong General Hospital & Guangdong Academy 
      of Medical Sciences, Guangzhou, 510080, People's Republic of China.
FAU - Li, Hao
AU  - Li H
AD  - Sun Yat-sen University Cancer Center, Guangzhou, 510060, People's Republic of 
      China.
AD  - State Key Laboratory of Oncology in South China, Guangzhou, 510060, People's 
      Republic of China.
AD  - Collaborative Innovation Center for Cancer Medicine, Guangzhou, 510060, People's 
      Republic of China.
FAU - Chen, Liang-Si
AU  - Chen LS
AD  - Department of Otorhinolaryngology, Guangdong General Hospital & Guangdong Academy 
      of Medical Sciences, Guangzhou, 510080, People's Republic of China.
FAU - Luo, Xiao-Ning
AU  - Luo XN
AD  - Department of Otorhinolaryngology, Guangdong General Hospital & Guangdong Academy 
      of Medical Sciences, Guangzhou, 510080, People's Republic of China.
FAU - Lu, Zhong-Ming
AU  - Lu ZM
AD  - Department of Otorhinolaryngology, Guangdong General Hospital & Guangdong Academy 
      of Medical Sciences, Guangzhou, 510080, People's Republic of China.
FAU - Zhang, Si-Yi
AU  - Zhang SY
AD  - Department of Otorhinolaryngology, Guangdong General Hospital & Guangdong Academy 
      of Medical Sciences, Guangzhou, 510080, People's Republic of China. 
      szhang555@hotmail.com.
FAU - Chen, Shao-Hua
AU  - Chen SH
AUID- ORCID: 0000-0003-3544-3138
AD  - Department of Otorhinolaryngology, Guangdong General Hospital & Guangdong Academy 
      of Medical Sciences, Guangzhou, 510080, People's Republic of China. 
      chenshaohua1168@163.com.
LA  - eng
GR  - A2018151/Medical Scientific Research foundation of Guangdong Province of China/
PT  - Journal Article
DEP - 20200824
PL  - England
TA  - BMC Cancer
JT  - BMC cancer
JID - 100967800
RN  - 0 (Biomarkers, Tumor)
RN  - 0 (MicroRNAs)
RN  - 0 (Mirn129 microRNA, human)
RN  - 0 (OTX1 protein, human)
RN  - 0 (Otx Transcription Factors)
SB  - IM
MH  - Animals
MH  - Biomarkers, Tumor/*genetics
MH  - Carcinogenesis/genetics
MH  - Cell Line, Tumor
MH  - Cell Proliferation/genetics
MH  - Disease Progression
MH  - Female
MH  - Follow-Up Studies
MH  - Gene Expression Regulation, Neoplastic
MH  - Gene Knockdown Techniques
MH  - Humans
MH  - Kaplan-Meier Estimate
MH  - Laryngeal Neoplasms/diagnosis/*genetics/mortality/surgery
MH  - Laryngectomy
MH  - Larynx/pathology/surgery
MH  - Male
MH  - Mice
MH  - MicroRNAs/*metabolism
MH  - Middle Aged
MH  - Otx Transcription Factors/*genetics
MH  - Retrospective Studies
MH  - Squamous Cell Carcinoma of Head and Neck/diagnosis/*genetics/mortality/surgery
MH  - Xenograft Model Antitumor Assays
PMC - PMC7446126
OTO - NOTNLM
OT  - Laryngeal squamous cell carcinoma
OT  - MiR-129-5p
OT  - Orthodenticle homeobox 1
OT  - Prognosis
OT  - Tumor progression
COIS- The authors declare that they have no competing interests.
EDAT- 2020/08/26 06:00
MHDA- 2021/04/15 06:00
PMCR- 2020/08/24
CRDT- 2020/08/26 06:00
PHST- 2020/04/14 00:00 [received]
PHST- 2020/08/09 00:00 [accepted]
PHST- 2020/08/26 06:00 [entrez]
PHST- 2020/08/26 06:00 [pubmed]
PHST- 2021/04/15 06:00 [medline]
PHST- 2020/08/24 00:00 [pmc-release]
AID - 10.1186/s12885-020-07279-1 [pii]
AID - 7279 [pii]
AID - 10.1186/s12885-020-07279-1 [doi]
PST - epublish
SO  - BMC Cancer. 2020 Aug 24;20(1):794. doi: 10.1186/s12885-020-07279-1.